New Website Details Harmful Effects of Salmon Farming Practices from Evidence-Based Research
ST. ANDREWS, NB, June 2, 2025 /CNW/ -- The Atlantic Salmon Federation and the North Atlantic Salmon Fund are proud to announce the launch of salmon.info, a comprehensive evidence-based resource for media professionals, policymakers, and conservationists about the harmful effects of the salmon farming practices that produce one of the world's most consumed fish.
"The salmon farming industry claims to be one of the most sustainable proteins on the planet with minimal environmental impact," said Neville Crabbe, executive director of communications at the Atlantic Salmon Federation. "Our goal for salmon.info is to provide accurate, accessible information on things the salmon farming industry doesn't talk about so that consumers who are eating farmed salmon are informed."
For example, it takes more than one kilogram of wild caught fish to grow one kilogram of farmed Atlantic salmon, and tens of millions of farmed fish die prematurely in sea cages every year - a staggering waste of animal life and resources. There are severe consequences from sea-cage salmon farms on other species, especially wild Atlantic salmon.
Key features of salmon.info include:
Access to over 300 vetted sources that provide in-depth insights into the impacts of open-net pen salmon farming.
An AI assistant that can search the site's database and answer questions from visitors.
Intuitive, user-friendly design with plain-language summaries of all major topics.
Visit www.salmon.info to learn more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
Media advisory - Minister Solomon to give remarks at groundbreaking ceremony for new Carbon Upcycling facility
MISSISSAUGA, ON, July 28, 2025 /CNW/ - The Honourable Evan Solomon, Minister of Artificial Intelligence and Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario, will give remarks at a groundbreaking ceremony for Carbon Upcycling's new facility. He will speak on behalf on the Honourable Melanie Joly, Minister of Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. Following the ceremony, Minister Solomon will host a brief media scrum. Date: Tuesday, July 29, 2025 Time: 10AM ET Location: Mississauga, Ontario Members of the media are asked to contact ISED Media Relations at [email protected] to receive event location details and confirm their attendance. Stay connected Find more services and information on the Innovation, Science and Economic Development Canada website. Follow Innovation, Science and Economic Development Canada on social media. X (Twitter): @ISED_CA | Facebook: Canadian Innovation | Instagram: @cdninnovation | SOURCE Innovation, Science and Economic Development Canada Contacts: Sofia Ouslis, Press Secretary l Office of the Minister of Artificial Intelligence, Digital Innovation and Federal Economic Development Agency of Southern Ontario, Attachée de presse l Ministre de l'IA, de l'Innovation numérique et de l'Agence fédérale de développement économique pour le Sud de l'Ontario, 343-542-0152 l [email protected]; Media Relations, Innovation, Science and Economic Development Canada, [email protected]
Cision Canada
9 hours ago
- Cision Canada
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions were delivered with high adherence and safety. Cognitive benefits were consistent across age, sex, ethnicity, heart health status and apolipoprotein E-e4 genotype. TORONTO, July 28, 2025 /CNW/ -- The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at risk of cognitive decline. Trial participants in the structured (STR) intervention showed greater improvement on global cognition compared to the self-guided (SG) intervention, protecting cognition from normal age-related decline for up to two years. The STR intervention differed from the SG intervention in intensity, structure, accountability and support provided. The results were reported for the first time today at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto and online. "Effects Of Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The U.S. POINTER Randomized Clinical Trial," was published in The Journal of the American Medical Association (JAMA) simultaneously with the report at AAIC 2025. U.S. POINTER is the first large-scale, randomized controlled clinical trial to demonstrate that an accessible and sustainable healthy lifestyle intervention can protect cognitive function in diverse populations in communities across the United States. "As the burden of dementia grows world-wide, U.S. POINTER affirms a vital public health message: healthy behavior has a powerful impact on brain health," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. "This is a critical public health opportunity. The intervention was effective across a broad, representative group — regardless of sex, ethnicity, APOE genetic risk, or heart health status — demonstrating its applicability and scalability for communities across the country," said Pike. "The positive results of U.S. POINTER encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in our fight against cognitive decline and possibly dementia." U.S. POINTER leadership acknowledges participants, their family members and study site staff for their unique and essential contributions: "You helped change what we know about brain health. Thanks to your dedication, time and support, U.S. POINTER delivered groundbreaking results. Your children, grandchildren and generations to come will benefit from the commitment you made." Both interventions focused on physical exercise, nutrition, cognitive challenge and social engagement, and heart health monitoring, but differed in intensity, structure, accountability and support provided. Structured lifestyle intervention. Participants attended 38 facilitated peer team meetings over two years, and were provided with a prescribed activity program with measurable goals for: aerobic, resistance and stretching exercise; adherence to the MIND diet; cognitive challenge through BrainHQ training and other intellectual and social activities; and regular review of health metrics and goal-setting with a study clinician. Self-guided lifestyle intervention. Participants attended six peer team meetings to encourage self-selected lifestyle changes that best fit their needs and schedules. Study staff provided general encouragement without goal-directed coaching. "The potential to improve cognition with fewer resources and lower participant burden is compelling. It highlights that while not everyone has the same access or ability to adhere to more intensive behavior interventions, even modest changes may protect the brain," said Laura D. Baker, Ph.D., Professor of Gerontology and Geriatrics, and Internal Medicine, at Wake Forest University School of Medicine and Advocate Health, and U.S. POINTER principal investigator. "These are the initial results. Over the coming weeks and months, study leadership will be exploring all of the data collected in the trial to paint an even more comprehensive picture of the U.S. POINTER intervention effects on brain health," Baker said. People with cognitive decline and dementia often have a variety of damaging changes in their brain. This means effective treatment will likely require a multi-pronged or combination strategy to address multiple disease mechanisms. "Complex diseases like heart disease and cancer use combination treatment strategies tailored to individual characteristics. The next generation of treatments for diseases like Alzheimer's will likely integrate drug and non-drug strategies. U.S. POINTER provides a strong foundation for such combination approaches," said Heather M. Snyder, Ph.D., Alzheimer's Association study primary investigator and senior vice president of medical and scientific relations. "While these results are fascinating and extremely hopeful, how they are rolled out to the public — especially those at risk for Alzheimer's and other diseases that cause dementia — needs to be handled with care and individual attention to tailor to the local environment," said Snyder. The Alzheimer's Association has invested nearly $50 million to lead this study to date, with additional support from the National Institute on Aging at the National Institutes of Health for add-on studies exploring imaging, vascular measures, sleep and gut microbiome-related health data. In addition to its investments to date, the Alzheimer's Association will invest more than $40 million over the next four years to continue to follow U.S. POINTER participants, and to bring U.S. POINTER interventions to communities across America. U.S. POINTER is a phase 3, five-site, two-year, single-blind randomized clinical trial of two lifestyle interventions in older adults at risk for dementia. U.S. POINTER was developed to assess whether the results of the FINGER study [ Lancet, 6-6-15] generalize to a larger, more diverse U.S. population at risk for cognitive decline and dementia, using culturally adapted protocols. The primary aim was to compare the effects of two multimodal lifestyle interventions on global cognitive function in 2,000+ at-risk older adults. Secondary aims assessed intervention effects on specific cognitive domains, and potential differences based on baseline cognition, sex, age, APOE-e4 genotype, and cardiovascular risk. The study was conducted at five geographically dispersed U.S. academic centers and health care systems in partnership with the Alzheimer's Association. Participant eligibility criteria were designed to enrich the risk of cognitive decline and included older age (60-79 years), sedentary lifestyle, suboptimal diet and cardiometabolic health, and family history of memory impairment. 2,111 participants were enrolled and randomized to STR (n=1,056) or SG (n=1,055). Mean age was 68.2 years, 68.9% were female, 30.8% were from ethnoracial minority groups. Seventy-eight percent (78%) reported a first-degree family history of memory loss, and 30% were APOE-e4 carriers. Retention was high, with 89% completing the final 2 year assessment. At two years, there was a statistically significant intervention group difference on the primary outcome. Global cognitive composite scores (primary outcome) increased over time in both groups but the improvement over time was statistically significant for a greater benefit for the STR versus SG: 0.029 SD per year (95% CI, 0.008-0.050, P =0.008). For secondary outcomes, the increase in executive function z-score was greater in STR than SG by 0.037 SD per year (95% CI, 0.010-0.064). Processing speed showed a similar trend but was not statistically significant. There were no group differences in memory. Looking ahead, the Association will build on the momentum of U.S. POINTER by launching several programs and initiatives, including: A personal brain health assessment tool. A virtual brain health training program for health care providers. A community recognition program for organizations championing brain health. A brain health roundtable that will unite leaders across health care, public health, community and corporate sectors to accelerate impact. About AAIC AAIC is the world's largest gathering of researchers from around the world focused on Alzheimer's and other diseases that cause dementia. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2025: AAIC 2025 newsroom: AAIC 2025 hashtag: #AAIC25 About the Alzheimer's Association The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit or call +1 800.272.3900.
Cision Canada
15 hours ago
- Cision Canada
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /CNW/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: Brain-Derived pTau Performance: The presentation will showcase data from the 1946 Birth Cohort featuring the new brain-derived pTau isoforms using the NULISAseq™ CNS Disease Panel 120 in both presymptomatic and post-AD diagnosis samples, highlighting the superior ability of brain-derived pTaus to predict Alzheimer's disease years before it was diagnosed Correlations with Disease Progression: Data will demonstrate the correlation between brain-derived pTau levels and amyloid and Tau PET imaging Biomarkers for neuropathologies and AD co-pathologies: Analysis of a unique cohort of patients with autopsy-confirmed pathologies with the NULISAseq™ CNS Disease Panel 120 identified biomarkers for detecting neuropathologies and AD co-pathologies. Preclinical research: The NULISAseq™ Mouse Panel 120 demonstrated utility in analysis of plasma and brain homogenate samples from multiple clinical models of AD. The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
